Stockscreener 앱 받기
12.22
2.09%
0.25
시간 외 거래:
12.19
-0.03
-0.25%
Dyne Therapeutics Inc 주식(DYN)의 최신 뉴스
Dyne Therapeutics Inc. Recovery Likely Here’s What Data ShowsTrade Risk Assessment & Safe Entry Momentum Stock Tips - beatles.ru
Dyne Therapeutics Inc. Approaches Support With Recovery in SightJuly 2025 Trends & Verified Momentum Stock Watchlist - thegnnews.com
Dyne Therapeutics (DYN) Maintains Hold Rating, $12 Price Target - AInvest
What Technical Tools Say About Dyne Therapeutics Inc. RecoveryJuly 2025 Analyst Calls & Risk Managed Trade Strategies - beatles.ru
Myotonic Dystrophy Pipeline 2025: MOA, ROA, FDA-Approved Drugs, and Clinical Trial Progress Assessment by DelveInsight | Dyne Therapeutics, Avidity Biosciences, Harmony Biosciences, AMO Pharma, Lupin - Barchart.com
Dyne Therapeutics Shares Rise 3.6% After FDA Grants Breakthrough Therapy Status - MSN
Dyne Therapeutics Receives FDA Breakthrough Therapy Designation for Duchenne Muscular Dystrophy Therapy - Yahoo Finance
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN - GlobeNewswire Inc.
Should value investors consider Dyne Therapeutics Inc.July 2025 PostEarnings & Safe Capital Growth Stock Tips - thegnnews.com
Pomerantz LLP investigates Dyne Therapeutics for potential securities fraud. - AInvest
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc.DYN - PR Newswire
Why is Dyne Therapeutics Inc. stock going up2025 EndofYear Setup & Consistent Profit Alerts - thegnnews.com
Can Dyne Therapeutics Inc. expand its profit margins2025 Volatility Report & Comprehensive Market Scan Reports - 선데이타임즈
Dyne Therapeutics Advances DMD Treatment with DYNE-251 Study - MSN
Short Interest Drops in Dyne Therapeutics Inc. After RallyJuly 2025 Setups & High Return Stock Watch Alerts - sundaytimes.kr
Dyne Therapeutics Inc. Shows Risk Reward Favoring UpsideLow Capital High Return Stock Plans Reviewed - 선데이타임즈
Dyne Therapeutics Trading Resumes - AInvest
Is Dyne Therapeutics Reaching New Heights? - StocksToTrade
Dyne Therapeutics price target lowered to $13 from $34 at Oppenheimer - TipRanks
Oppenheimer Lowers Dyne Therapeutics (DYN) Price Target to $13.00 | DYN Stock News - GuruFocus
Oppenheimer Lowers Dyne Therapeutics (DYN) Price Target to $13.0 - GuruFocus
Dyne Therapeutics (DYN) Earns Breakthrough Therapy Status for DY - GuruFocus
Dyne Reports Wider Loss in Fiscal Q2 - AOL.com
Dyne Therapeutics stock gains as DYNE-251 receives FDA breakthrough designation - Investing.com Canada
Dyne Therapeutics (DYN) Gains FDA Breakthrough Status for DYNE-2 - GuruFocus
Dyne Therapeutics stock rises after FDA grants breakthrough therapy status By Investing.com - Investing.com Australia
Dyne Therapeutics stock rises after FDA grants breakthrough therapy status - Investing.com
Dyne gets FDA breakthrough therapy status for DMD therapy - Seeking Alpha
Dyne Therapeutics (DYN) Earns Breakthrough Therapy Status for DYNE-251 - GuruFocus
Dyne Therapeutics Gains FDA Breakthrough Designation for DYNE-251 - TipRanks
Dyne Therapeutics Announces Breakthrough Therapy Designation For DYNE-251 - Nasdaq
Dyne Therapeutics Announces FDA Breakthrough Therapy Designation - GuruFocus
Dyne Therapeutics Announces FDA Breakthrough Therapy Designation For Dyne-251 In Duchenne Muscular Dystrophy - TradingView
Dyne Therapeutics Receives FDA Breakthrough Therapy Designation for DYNE-251 in Duchenne Muscular Dystrophy - Quiver Quantitative
Dyne Therapeutics Announces FDA Breakthrough Therapy Designation for DYNE-251 in Duchenne Muscular Dystrophy (DMD) - The Manila Times
Dyne Therapeutics Announces FDA Breakthrough Therapy - GlobeNewswire
Dyne Therapeutics: Promising Advancements and FDA Support Drive Buy Rating - TipRanks
What makes Dyne Therapeutics Inc. stock price move sharplyAchieve breakthrough profits with expert advice - Jammu Links News
What is Dyne Therapeutics Inc. company’s growth strategyTremendous growth opportunities - Jammu Links News
Is it the right time to buy Dyne Therapeutics Inc. stockMarket-beating returns - Jammu Links News
Why is Dyne Therapeutics Inc. stock attracting strong analyst attentionAchieve breakthrough gains with expert advice - Jammu Links News
Should I hold or sell Dyne Therapeutics Inc. stock in 2025Build wealth steadily with proven investment techniques - Jammu Links News
What is the risk reward ratio of investing in Dyne Therapeutics Inc. stockAchieve breakthrough investment performance - Jammu Links News
How many analysts rate Dyne Therapeutics Inc. as a “Buy”Unlock powerful market insights for success - jammulinksnews.com
Does Dyne Therapeutics (DYN) Have the Potential to Rally 285.57% as Wall Street Analysts Expect? - MSN
Dyne Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights - ADVFN Brasil
Pomerantz Investigates Dyne Therapeutics for Securities Fraud. - AInvest
Stifel Downgrades Dyne Therapeutics to Buy, Lowers PT to $36. - AInvest
Stifel lowers Dyne Therapeutics stock price target to $36 on endpoint changes - Investing.com Canada
Dyne Therapeutics (DYN) Gets a Buy from Scotiabank - The Globe and Mail
Dyne Therapeutics (DYN) Keeps 'Outperform' Rating Amid RBC Capital Price Target Cut to $23.00 - AInvest
1.55%
0.38%
자본화:
|
볼륨(24시간):